Earnings Miss Highlights Werewolf Therapeutics' Financial Struggles Werewolf Therapeutics reported a full-year 2024 net loss of $70.5 million, with a per-share loss of $1.63, missing expectations. Despite revenue forecasts projecting 64% annual growth over the next three years, the company faces mounting challenges, including widening losses and investor scrutiny over its long-term viability.56